ReviewRheumatology advances in practice2024
Current and future advances in practice: IgG4-related disease.
Review in Rheumatology advances in practice, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 54 citations in OpenAlex.
- IgG4-related disease in gastroenterology: from pathogenesis to clinical management and long-term outcomes.Journal of gastroenterology · 2026Review
- Efficacy and Safety of Obexelimab to Treat IgG4-Related Disease: Protocol for a Global, Randomized, Placebo-Controlled Trial.Rheumatology and therapy · 2026Article
- IgG4-related disease presenting as a gastric mass necessitating total gastrectomy: a case report.Journal of surgical case reports · 2026Article
- Comparable effectiveness of intensive intravenous and less intensive immunosuppressive treatment in retroperitoneal fibrosis: a retrospective real-world cohort study.Rheumatology international · 2026Observational
- Management of IgG4-Related Disease.Current rheumatology reports · 2026Review
- Review
- Article
- Toward audit-ready care in IgG4-related disease: redefining relapse, damage, and access in the biologic era.Rheumatology international · 2026Article
- Immunological Biomarkers to Assess Activity and Treatment Response in IgG4-Related Disease.Medicina (Kaunas, Lithuania) · 2026Article
- Real-world safety profile of bisoprolol: signal detection and demographic stratification using the FAERS database.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Intralesional Corticosteroid Therapy for Isolated Immunoglobulin G4-Related Esophageal Involvement: A Novel Approach to a Rare Condition.ACG case reports journal · 2026Article
- Correlations between IgG4-related disease, autoimmune pancreatitis, and allergic diseases.Frontiers in immunology · 2026Review
- A case of an immunoglobulin G4 related inflammatory pseudotumor involving the clivus and the nasopharynx: A challenging case of a perplexing entity with an exhaustive overview.Brain & spine · 2026Article
- From inflammatory initiation to fibrotic remodeling: mechanisms and precision therapeutic strategies in otorhinolaryngologic involvement of IgG4-related disease.Frontiers in medicine · 2026Review
- Clinically Isolated IgG4-Related Disease of the Larynx: A Rare Cause of Progressive Dysphonia.Cureus · 2025Article
- Perinephric myxoid tumour of fat and IgG4-related disease: when retroperitoneal fat conceals two truths. A case report of a tricky diagnosis.BJR case reports · 2025Article
- New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach.Journal of clinical medicine · 2025Review
- The Incidence of IgG4-Related Disease in Slovenia-Single-Centre Experience.Biomedicines · 2025Article
- Nutritional Management in Chronic Pancreatitis: From Exocrine Pancreatic Insufficiency to Precision Therapy.Nutrients · 2025Review
- IgG4-related disease with interstitial nephritis in a patient with metastatic melanoma following immune checkpoint inhibitor treatment: a case report.BMC rheumatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
IgG4-related disease (IgG4-RD) is an increasingly recognized cause of fibroinflammatory lesions in patients of diverse racial and ethnic backgrounds and is associated with an increased risk of death. The aetiology of IgG4-RD is incompletely understood, but evidence to date suggests that B and T cells are important players in pathogenesis, both of which are key targets of ongoing drug development programmes. The diagnosis of IgG4-RD requires clinicopathological correlation because there is no highly specific or sensitive test. Glucocorticoids are highly effective, but their use is limited by toxicity, highlighting the need for studies investigating the efficacy of glucocorticoid-sparing agents. B cell-targeted therapies, particularly rituximab, have demonstrated benefit, but no randomized clinical trials have evaluated their efficacy. If untreated or under-treated, IgG4-RD can cause irreversible organ damage, hence close monitoring and consideration for long-term immunosuppression is warranted in certain cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.